Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
=== Tax implications of transaction accounting === In February 2007, Merck paid $2.3 billion to the Internal Revenue Service to settle a tax dispute over the accounting treatment of transactions between 1993 and 2001.
== Mechanisms and functions of phosphorylation == Phosphorylation introduces a charged and hydrophilic group in the side chain of amino acids, possibly changing a protein's structure by altering interactions with nearby amino acids. Some proteins such as p53 contain multiple phosphorylation sites, facilitating complex, multi-level regulation. Because of the ease with which proteins can be phosphorylated and dephosphorylated, this type of modification is a flexible mechanism for cells to respond to external signals and environmental conditions. Kinases phosphorylate proteins and phosphatases dephosphorylate proteins. Many enzymes and receptors are switched "on" or "off" by phosphorylation and dephosphorylation. Reversible phosphorylation results in a conformational change in the structure in many enzymes and receptors, causing them to become activated or deactivated. Phosphorylation usually occurs on serine, threonine, tyrosine and histidine residues in eukaryotic proteins. Histidine phosphorylation of eukaryotic proteins appears to be much more frequent than tyrosine phosphorylation. In prokaryotic proteins phosphorylation occurs on the serine, threonine, tyrosine, histidine, arginine or lysine residues. The addition of a phosphate (PO43-) molecule to a non-polar R group of an amino acid residue can turn a hydrophobic portion of a protein into a polar and extremely hydrophilic portion of a molecule.
On September 25, Xi and Peng returned to the White House with Donald and Melania Trump. They then attended a tea ceremony in the Red Room. Trump said US farmers "are going to be very happy" with the talks, adding "A lot of very positive things happened, but America is very happy about this visit and I’m sure China is very happy also". He said "We’ve had a tremendous visit from two spectacular people" and "We’ve really enjoyed it and I think we’ve been tremendous strides. We’ve made great strides, very positive for both countries." During this tea ceremony, Xi said that he and Trump "are like two people who are charting the course for the great ship of China-U.S. relations." Xi also confirmed that two leaders will to see each other later this year in twice, including APEC summit in Shenzhen and G20 Summit in Miami. Later, Xi and Trump visited the National Archives, and viewed the Declaration of Independence, the Constitution and the Bill of Rights. According to the NPR, a table that included a temporary display showcasing a brick from the Great Wall of China and an 19th century scroll sent by a Qing emperor was removed because the display also planned to show the Treaty of San Francisco, which China considers as illegitimate because it was not a signatory. Other documents, including Six Assurances and the Three Communiqués, were also discussed for display, but ultimately not included.
== History == Oat products have been used for centuries for medicinal and cosmetic purposes; however, the specific role of β-glucan was not explored until the 20th century. β-glucans were first discovered in lichens, and shortly thereafter in barley. After joining Agriculture and Agri-Food Canada in 1969, Peter J Wood played an instrumental role in isolating and characterizing the structure and bioactive properties of oat β-glucan. A public interest in oat β-glucan arose after its cholesterol lowering effect was reported in 1984. In 1997, after reviewing 33 clinical studies performed over the previous decades, the FDA approved the claim that intake of at least 3 g of β-glucan from oats per day "as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." This marked the first time a public health agency claimed dietary intervention can actually help prevent disease. This health claim mobilized a dietary movement as physicians and dietitians for the first time could recommend intake of a specific food to directly combat disease. Since then, oat consumption has continued to gain traction in disease prevention with noted effects on ischemic heart disease and stroke prevention, but also in other areas like BMI reduction, blood pressure lowering and highly corroborated evidence for reduced blood serum cholesterol.
Sources: en.wikipedia.org
In osteology, the osteon or haversian system (; named for Clopton Havers) is the fundamental functional unit of much compact bone. Osteons are roughly cylindrical structures that are typically between 0.25 mm and 0.35 mm in diameter. Their length is often hard to define, but estimates vary from several millimeters to around 1 centimeter. They are present in many bones of most mammals and some bird, reptile, and amphibian species.
== Detection == Alan Fryday (1991) outlined a technique for the detection of confluentic acid in lichen samples. This method involves placing a section of the lichen's thallus or apothecium (fruiting body) on a microscope slide, which is then saturated with a 10% potassium hydroxide (KOH) solution. When examined under a compound microscope at 40x magnification, a distinctive 'halo' of small oil droplets or bubbles emanating from the tissue section indicates the presence of confluentic acid. The oil droplets generated during this detection process consist of 4-O-methylolivetonide, a compound that is insoluble in potassium hydroxide solution. This substance forms as a result of confluentic acid undergoing hydrolysis in the presence of potassium hydroxide. This test is useful in distinguishing between morphologically similar yet chemically distinct species within the genus Porpidia.
In pediatric patients, the pump speed should be kept at low side, according to patient blood output capacity, and the clotting with heparin dose should be carefully monitored. The high flux dialysis (see below) is not recommended for pediatric patients. In children, hemodialysis must be individualized and viewed as an "integrated therapy" that considers their long-term exposure to chronic renal failure treatment. Dialysis is seen only as a temporary measure for children compared with renal transplantation because this enables the best chance of rehabilitation in terms of educational and psychosocial functioning. Long-term chronic dialysis, however, the highest standards should be applied to these children to preserve their future "cardiovascular life"—which might include more dialysis time and on-line hemodiafiltration online hdf with synthetic high flux membranes with the surface area of 0.2 m2 to 0.8 m2 and blood tubing lines with the low volume yet large blood pump segment of 6.4/8.0 mm, if we are able to improve on the rather restricted concept of small-solute urea dialysis clearance.
Sir Bernard Rawdon Reilly (1 April 1937 – 24 October 1940) John Hathorn Hall (24 October 1940 – 1 January 1945) (From 2 December 1940, Sir John Hathorn Hall) Reginald Stuart Champion (1 January 1945 – 1950) (From 1 January 1946, Sir Reginald Stuart Champion) William Allmond Codrington Goode (1950 – April 1951) (Acting) Sir Tom Hickinbotham (April 1951 – 13 July 1956) Sir William Luce (13 July 1956 – 23 October 1960) Sir Charles Johnston (23 October 1960 – 18 January 1963)
A dough conditioner (also called a flour treatment agent, improving agent or bread improver) is any substance added to bread dough to strengthen its texture or otherwise improve it in some way. Dough conditioners may include enzymes, yeast nutrients, mineral salts, oxidants and reductants, bleaching agents and emulsifiers. Flour treatment agents are used to increase the speed of dough rising and to improve the strength and workability of the dough.
Sources: en.wikipedia.org
Diethyl ether could also be mixed with other anesthetic agents such as chloroform to make C.E. mixture, or chloroform and alcohol to make A.C.E. mixture. In the mid-20th century the growing use of electrical cauterization in surgery necessitated a switch to non-flammable anesthesia. In the 21st century, ether is rarely used. The use of flammable ether was displaced by nonflammable fluorinated hydrocarbon anesthetics. Halothane was the first such anesthetic developed and other currently used inhaled anesthetics, such as isoflurane, desflurane, and sevoflurane, are halogenated ethers. Diethyl ether was found to have undesirable side effects, such as post-anesthetic nausea and vomiting. Modern anesthetic agents reduce these side effects.
p3 peptide is known to have a role in AD and DS, however it has not been clearly determined yet. In order to study the function of p3 peptide in AD, specific antibodies’ location techniques have been used to determine its absence or sparseness in aged non-AD brains. As it turns out, p3 peptide is prevalent in selected areas of AD brain in diffuse deposits and in a subset of dystrophic neuritis, both located in the temporal lobe limbic system. Although p3 peptide can assemble into fibrillar aggregates, its hydrophobic properties make it unable to rest in oligomeric forms. This might explain why p3 has no impact on synaptic function and therefore in AD, since it is a non-amyloidogenic product of APP. Despite this fact, p3 has been proved to have a role in formation of non-fibrillar deposits or lesions associated with DS, another neurological disorder that progresses at a faster rate than AD. Accordingly, DS patients have three copies of the APP gene, as they have three copies of the chromosome 21, so APP is overexpressed in the brain and AD develops at an early age. The disruption of the normal function of APP in AD and, consequently, in DS, including overexpression or altered processes, is the most likely explanation for amyloid plaque formation and subsequent neuronal loss and dementia, associated to memory, spatial disorientation and deterioration of intellectual capacity. Since p3 has not been studied deeply, there are different opinions about its role in brain.
==== Addiction ==== Whether caffeine can result in an addictive disorder depends on how addiction is defined. Compulsive caffeine consumption under any circumstances has not been observed, and caffeine is therefore not generally considered addictive. Some diagnostic sources, such as the ICD-9 and ICD-10, include a classification of caffeine addiction under a broader diagnostic model. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, with people preferring placebo over caffeine in a study on drug abuse liability published in an NIDA research monograph. Some state that research does not provide support for an underlying biochemical mechanism for caffeine addiction. Other research states it can affect the reward system. "Caffeine addiction" was added to the ICD-9 and ICD-10. However, its addition was contested with claims that this diagnostic model of caffeine addiction is not supported by evidence. The American Psychiatric Association's DSM-5 does not include the diagnosis of a caffeine addiction but proposes criteria for the disorder for more study. As of 2021, the World Health Organization does not classify caffeine as an addictive substance.
=== Controversial associations === Beyond the well established link between benzodiazepines and psychomotor impairment resulting in motor vehicle accidents and falls leading to fracture; research in the 2000s and 2010s has raised the association between benzodiazepines (and Z-drugs) and other, as of yet unproven, adverse effects including dementia, cancer, infections, pancreatitis and respiratory disease exacerbations.
Peukert argued there was a disconnect between the popular image today of the Nazi era as a time of unparalleled horror vs. the way in which most ordinary Germans remembered it as a time of benign "normality", and that studying Alltagsgeschichte would explore what the Third Reich was actually like in "everyday life". In the early 1980s, Alltagsgeschichte exploded in popularity in West Germany with numerous work groups being set, usually by left-wing groups, to explore the history of their home towns in the Nazi era. The study of Alltagsgeschichte was greatly influenced by the History Workshop movement in Britain set up by the Marxist historian E.P. Thompson and like the British Workshop groups, many involved in the Alltagsgeschichte study groups were not historians with a disproportional number of the volunteers being high-school students. The American historian Mary Nolan wrote with some envy about the way in which thousands of German high school students became involved in the Alltagsgeschichte study groups, observing that it was simply inconceivable that thousands of American high school students would join study groups to research the histories of their home towns in the 1930s-1940s as most Americans have no interest in history. In 1984, Peukert was awarded the annual culture prize given by the city of Essen for his work with a history workshop group in Essen.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。